Kazia’s $50 Million Private Placement Extends Cash Runway Into 2028: What This Means for Clinical Progress
Market Chameleon (Tue, 2-Dec 9:21 AM)
Kazia Therapeutics Delivers Rare Immune-Complete Response in Metastatic TNBC: What Sets This Milestone Apart?
Market Chameleon (Wed, 19-Nov 9:55 AM)
Kazia Therapeutics Reports Rare Immune-Complete Response in Stage IV Breast Cancer: What Does This Mean for Future Oncology Treatments?
Market Chameleon (Wed, 19-Nov 7:05 AM)
Kazia Targets FDA Type C Meeting as Overall Survival Data in GBM Suggests Pathway for Conditional Approval
Market Chameleon (Mon, 27-Oct 8:02 AM)
Kazia Therapeutics Expands Pipeline with First-in-Class PD-L1 Protein Degrader—NDL2 Aims to Overcome Immunotherapy Resistance
Market Chameleon (Tue, 7-Oct 8:54 AM)
Kazia Therapeutics Highlights 86% Tumor Reduction in Metastatic TNBC Patient After Three Weeks of Paxalisib Combination Therapy
Market Chameleon (Thu, 2-Oct 8:48 AM)
